Home » Healthcare » Pharmaceuticals » Dravet Syndrome Treatment Market

Dravet Syndrome Treatment Market By Type of Drugs (Topiramate, Levetiracetam, Zonisamide, Valproic Acid, Clobazam, Clonzepam, Stiripentol, Cannabidiol) – Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Published: | Report ID: 5400 | Report Format : PDF

Dravet syndrome treatment accounted for a market value of US$ 209.2 million in 2018 and is expected to grow at an 11.7% CAGR from 2019 to 2027. The current treatment options for Dravet syndrome focus on the symptomatic relief associated with epileptic seizures. However, recent drug approvals for Dravet syndrome treatment have increased the overall market size and attracted the attention of major pharmaceutical companies.

In June 2018, Epidiolex (Cannabidiol) from GW Pharmaceuticals was approved by the USFDA specifically for Dravet syndrome. Epidiolex was followed by Fintepla (earlier ZX008), which is awaiting approval in the United States and Europe, and boosted Zogenix shares by 20.5% in March 2019. Thus, overall target-specific drugs are entering the Dravet syndrome treatment horizon, with their market growth expected to spurt from 2019 to 2027.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Market Synopsis

Stiripentol and cannabidiol will assist in the significant growth of the Dravet syndrome treatment market throughout the forecast period.

The U.S. Food and Drug Administration (FDA) approved stiripentol (Diacomit) in August 2018 to treat seizures associated with Dravet syndrome. Stiripentol’s market share is growing at a significant rate post-2018 due to its higher efficiency, safety, and prolonged relief from seizures.

In addition to that, a cannabidiol brand named Epidiolex, manufactured by GW Research Ltd., was approved in June 2018. Cannabidiol is the first FDA-approved drug that contains a purified drug substance derived from marijuana. Thus, the overall environment of the Dravet syndrome treatment market is growing significantly due to a strong drug pipeline and recently approved drugs.

North America dominated the overall global market, especially due to recent drug approvals and developed diagnostic technology.

In 2017, North America dominated the market and was expected to maintain its dominance throughout the forecast period due to key market drivers such as rising awareness related to neurological disorders, increasing demand for target-specific drugs to treat Dravet syndrome, and high accessibility and adaptability for recently launched drugs.

During the forecast period from 2019 to 2027, Asia-Pacific is expected to grow significantly throughout the forecast period due to increasing awareness related to Dravet syndrome coupled with the developing diagnostic technologies in the neurological disease area.

Periods of History and Forecast

The Dravet syndrome treatment market was analyzed considering current market trends for the base year of 2018,and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises quantitative and qualitative data associated with the Dravet syndrome treatment market, along with key market dynamics covering market opportunities, drivers, and restraints that possess their own positive and negative effects. An elaborative analysis of market drivers, challenges, and opportunities based on country-level and regional segmentation is covered in the current scope of the report.

This report comprises detailed data related to the global Dravet syndrome treatment market, segmented by such factors as drug type and geography. The report also includes a competitive analysis of the major companies present in the Dravet syndrome treatment market, including detailed data related to the competitive landscape of the market and the recent strategies and products entering the market.

The key market players involved in the Dravet syndrome treatment industry were studied based on financial data, product portfolios, current press releases, and key market strategies. This report also covers attractive investment propositions analyzed based on an exclusive geographical PESTEL analysis. Major companies included in the report are GW Pharmaceuticals Plc., Ovid Therapeutics, PTC Therapeutics, Inc., Epygenix Therapeutics, Inc., Zogenix, Inc., Takeda Pharmaceutical Company Ltd., Biocodex S.A., OPKO Health Inc., and Biscayne Neurotherapeutics, Inc., among others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key questions are answered in this report.

  • Which is the most preferred drug to treat Dravet syndrome and why?
  • What are the recent market strategies followed by the key companies and the competitive landscape of the Dravet syndrome treatment market?
  • Which are the current and future major geographical markets (regions and countries) for Dravet syndrome treatment?
  • Which is the largest and fastest-growing Dravet syndrome treatment segment globally?
  • What are the drivers, restraints, and opportunities in the Dravet syndrome treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global DST Market Portraiture
2.2. Global DST Market, by Type of Drug, 2017 (US$ Mn)
2.3. Global DST Market, by Geography, 2017 Vs 2027 (Value %)

Chapter 3. Global Dravet Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Dravet Syndrome Treatment (DST) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Topiramate
4.3. Levetiracetam
4.4. Zonisamide
4.5. Valproic Acid
4.6. Clobazam
4.7. Clonzepam
4.8. Stiripentol
4.9. Cannabidiol

Chapter 5. Global Dravet Syndrome Treatment (DST) Market, Pipeline Analysis
5.1. Overview
5.2. ZX008 (Zogenix) – Phase III
5.3. Ataluren/Translarna (PTC Therapeutics)
5.4. EPX200 (EpyGenix) – Phase II
5.5. EPX100 (EpyGenix) – Preclinical
5.6. TAK935 (Ovid & Takeda) – Phase II
5.7. TANGO/SCN1A ASO (Stoke Therapeutics) – Preclinical
5.8. SPN-817/BIS-001/Huperzine A (Supernus Pharmaceuticals) – Phase I
5.9. OPK88001/CUR-1916 (OPKO Health) – Preclinical
5.10. SAGE-324 (Sage Therapeutics) – Preclinical
5.11. XEN901 (Xenon Pharmaceuticals)

Chapter 6. Global Dravet Syndrome Treatment (DST) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America DST Market Analysis, 2017 – 2027
6.2.1. North America DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.2.2. North America DST Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe DST Market Analysis, 2017 – 2027
6.3.1. Europe DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.3.2. Europe DST Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific DST Market Analysis, 2017 – 2027
6.4.1. Asia Pacific DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific DST Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America DST Market Analysis, 2017 – 2027
6.5.1. Latin America DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.5.2. Latin America DST Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) DST Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa DST Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.6.2. MEA DST Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. GW Pharmaceuticals Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Ovid Therapeutics
7.3. PTC Therapeutics, Inc.
7.4. Epygenix Therapeutics, Inc.
7.5. Zogenix, Inc.
7.6. Takeda Pharmaceutical Company Ltd.
7.7. Biocodex S.A.
7.8. OPKO Health Inc.
7.9. Biscayne Neurotherapeutics, Inc.
7.10. Stoke Therapeutics
7.11. Sage Therapeutics
7.12. Xenon Pharmaceuticals

List of Figures

FIG. 1 Dravet Syndrome Treatment (DST): Market Segmentation
FIG. 2 Global DST Market Share, by Type of Drugs, 2018 (US$ Mn)
FIG. 3 Global DST Market, by Geography, 2018 Vs 2027 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2018
FIG. 5 Market Competition Landscape, by Key Players, 2018
FIG. 6 Global Topiramate Market for DST, 2017 – 2027 (US$ Mn)
FIG. 7 Global Levetiracetam Market for DST, 2017 – 2027 (US$ Mn)
FIG. 8 Global Zonisamide Market for DST, 2017 – 2027 (US$ Mn)
FIG. 9 Global Valproic Acid Market for DST, 2017 – 2027 (US$ Mn)
FIG. 10 Global Clobazam Market for DST, 2017 – 2027 (US$ Mn)
FIG. 11 Global Clonzepam Market for DST, 2017 – 2027 (US$ Mn)
FIG. 12 Global Stiripentol Market for DST, 2017 – 2027 (US$ Mn)
FIG. 13 Global Cannabidiol Market for DST, 2017 – 2027 (US$ Mn)
FIG. 14 Global ZX008 Market for DST, Till 2027 (US$ Mn)
FIG. 15 U.S. DST Market, 2017 – 2027 (US$ Mn)
FIG. 16 Canada DST Market, 2017 – 2027 (US$ Mn)
FIG. 17 U.K. DST Market, 2017 – 2027 (US$ Mn)
FIG. 18 Germany DST Market, 2017 – 2027 (US$ Mn)
FIG. 19 Rest Of Europe DST Market, 2017 – 2027 (US$ Mn)
FIG. 20 Japan DST Market, 2017 – 2027 (US$ Mn)
FIG. 21 China DST Market, 2017 – 2027 (US$ Mn)
FIG. 22 Rest Of Asia Pacific DST Market, 2017 – 2027 (US$ Mn)
FIG. 23 Brazil DST Market, 2017 – 2027 (US$ Mn)
FIG. 24 Mexico DST Market, 2017 – 2027 (US$ Mn)
FIG. 25 Rest Of Latin America DST Market, 2017 – 2027 (US$ Mn)
FIG. 26 GCC DST Market, 2017 – 2027 (US$ Mn)
FIG. 27 Rest Of Middle East And Africa DST Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Dravet Syndrome Treatment (DST) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 2 North America DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 3 North America DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 4 Europe DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 5 Europe DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Asia Pacific DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 7 Asia Pacific DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Latin America DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 9 Latin America DST Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Middle East & Africa DST Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
TABLE 11 Middle East And Africa DST Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 12 GW Pharmaceuticals Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Ovid Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 PTC Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Epygenix Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Zogenix, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Takeda Pharmaceutical Company Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Biocodex S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 OPKO Health Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Biscayne Neurotherapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Stoke Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Sage Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Xenon Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Question

What is the size of Dravet Syndrome Treatment Market?

The market for Dravet Syndrome Treatment Market is expected to reach USD$ 209.2 Mn in 2027.

What is the Dravet Syndrome Treatment Market CAGR?

The Dravet Syndrome Treatment Market is expected to see significant CAGR growth over the coming years, at 11.7%.

What is the Forecast period considered for Dravet Syndrome Treatment Market?

The report is forecasted from 2019 -2027.

What is the base year considered for Dravet Syndrome Treatment Market?

The base year of this report is 2018.

Who are the major players in this market?

Denso Corporation, Delphi Technologies, Magna Infotech, Panasonic Corporation, General Electric, Qualcomm, Inc. are some of the major players in the global market.

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

US Retail Pharmacy Market

Published:
Report ID: 32801

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

OTC Cough Cold And Allergy Medicine Market

Published:
Report ID: 20062

Heart Health Supplements Market

Published:
Report ID: 6184

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN